Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.

Autor: Zackova D; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Klamova H; Institute of Hematology and Blood Transfusion, Praha, Czech Republic., Belohlavkova P; 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Stejskal L; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic., Necasova T; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic., Semerad L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Weinbergerova B; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Srbova D; Institute of Hematology and Blood Transfusion, Praha, Czech Republic., Voglova J; 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Cicatkova P; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Sustkova Z; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Hornak T; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Baranova J; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic., Prochazkova J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.; Central European Institute of Technology, Brno, Czech Republic.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2021 Jan; Vol. 62 (1), pp. 194-202. Date of Electronic Publication: 2020 Oct 06.
DOI: 10.1080/10428194.2020.1827242
Abstrakt: To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje